AQST
Aquestive Therapeutics Inc
NASDAQ: AQST · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC
$4.16
-5.07% today
Updated 2026-06-05
Market cap
$493.02M
P/E ratio
—
P/S ratio
9.81x
EPS (TTM)
$-0.61
Dividend yield
—
52W range
$3 – $8
Volume
1.5M
WallStSmart proprietary scores
28
out of 100
Grade: F
Strong Sell
Investment rating
5.3
Growth
C+6.5
Quality
B2.5
Profitability
F4.0
Valuation
C2/9
Piotroski F-Score
Weak
-4.2
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →202 stocks currently score above 75
Price targets
Analyst target
$8.89
+113.70%
12-Month target
—
—
Intrinsic (DCF)
$2.55
Margin of safety
-49.80%
2 Strong Buy7 Buy0 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Revenue growth 65.70% QoQ
+ Debt/equity -3.92x — low leverage
Risks
- Piotroski 2/9 — weak financial health
- Altman Z -4.23 — distress zone
- Thin margins at -137.10%
- Negative free cash flow $-14.86M
- 49.80% above intrinsic value
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $47.68M | $50.58M | $57.56M | $44.55M | $50.27M |
| Net income | $-54.41M | $-7.87M | $-44.14M | $-83.78M | $-8.06M |
| EPS | — | — | — | — | $-0.61 |
| Free cash flow | $-12.31M | $-7.38M | $-35.92M | $-52.99M | $-14.86M |
| Profit margin | -114.11% | -15.56% | -76.68% | -188.09% | -137.10% |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-05-07 | BRAENDER, LORI J | Sale | 135,690 | $4.23 |
| 2026-05-05 | TOTH, A ERNEST JR | Sale | 92,652 | $4.18 |
| 2026-05-05 | JUNG, CASSIE | Sale | 72,734 | $4.18 |
Peer comparison
Smart narrative
Aquestive Therapeutics Inc trades at $4.16. Our Smart Value Score of 28/100 indicates the stock is weak. The company scores 2/9 on the Piotroski F-Score. With an Altman Z-Score of -4.23, it sits in the distress. TTM revenue stands at $50.27M. with profit margins at -137.10%. Our DCF model estimates intrinsic value at $2.55.
Frequently asked questions
What is Aquestive Therapeutics Inc's stock price?
Aquestive Therapeutics Inc (AQST) trades at $4.16, on a P/S of 9.8x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Aquestive Therapeutics Inc overvalued?
Aquestive Therapeutics Inc carries a Smart Value Score of 28/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read. On valuation specifically, our conservative DCF puts intrinsic value at $2.55 against the $4.16 price, so on cash flow terms the market is paying a premium for Aquestive Therapeutics Inc's growth. The Strong Sell rating reflects that growth and quality, while the DCF flags that the price already assumes a lot.
What is the price target of Aquestive Therapeutics Inc (AQST)?
The 12-month analyst consensus target is $8.89, about 113.7% above the current $4.16. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is the intrinsic value of Aquestive Therapeutics Inc (AQST)?
Our DCF model estimates intrinsic value at $2.55, a -49.8% margin of safety versus today's $4.16. Intrinsic value is what the projected cash flows are worth today. A negative reading means the price is running ahead of that conservative estimate, leaving little downside cushion if growth slows.
What is Aquestive Therapeutics Inc's revenue?
Aquestive Therapeutics Inc's trailing twelve-month revenue is $50.27M. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Altman Z-Score?
Aquestive Therapeutics Inc's Altman Z-Score is -4.23, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryDRUG MANUFACTURERS - SPECIALTY & GENERIC
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio9.81x
ROE—
Beta1.50
50D MA$4.15
200D MA$4.88
Shares out0.13B
Float0.11B
Short ratio—
Avg volume1.5M
Performance
1 week+0.00%
1 month-4.84%
3 months-2.24%
YTD-39.16%
1 year—
3 years—
5 years—